Birdwatch Archive - Rating Details

Birdwatch Note Rating

2024-01-15 08:06:41 UTC - NOT_HELPFUL

Rated by Participant: 062843FD0D10F2EEB221F0F752FB122BE003548B9C65030784C44DC3F4DE2A2A
Participant Details

Original Note:

Notzulassung ist falsch. Bedingte Zulassung ist übliches Vorgehen bei Erstzulassungen. "Die EU-Kommission hat am 28. Januar 2022 eine bedingte Zulassung für das orale antivirale Arzneimittel Paxlovid® (Nirmatrelvir + Ritonavir) zur Behandlung von COVID-19 erteilt." https://www.bfarm.de/DE/Arzneimittel/Arzneimittelinformationen/covid-19-arzneimittel.html

All Note Details

Original Tweet

All Information

noteId - 1746801901562126555
participantId -
raterParticipantId - 062843FD0D10F2EEB221F0F752FB122BE003548B9C65030784C44DC3F4DE2A2A
createdAtMillis - 1705306001213
version - 2
agree - 0
disagree - 0
helpful - 0
notHelpful - 0
helpfulnessLevel - NOT_HELPFUL
helpfulOther - 0
helpfulInformative - 0
helpfulClear - 0
helpfulEmpathetic - 0
helpfulGoodSources - 0
helpfulUniqueContext - 0
helpfulAddressesClaim - 0
helpfulImportantContext - 0
helpfulUnbiasedLanguage - 0
notHelpfulOther - 0
notHelpfulIncorrect - 0
notHelpfulSourcesMissingOrUnreliable - 0
notHelpfulOpinionSpeculationOrBias - 0
notHelpfulMissingKeyPoints - 1
notHelpfulOutdated - 0
notHelpfulHardToUnderstand - 0
notHelpfulArgumentativeOrBiased - 0
notHelpfulOffTopic - 0
notHelpfulSpamHarassmentOrAbuse - 0
notHelpfulIrrelevantSources - 0
notHelpfulOpinionSpeculation - 0
notHelpfulNoteNotNeeded - 1
ratingsId - 1746801901562126555062843FD0D10F2EEB221F0F752FB122BE003548B9C65030784C44DC3F4DE2A2A